Ferric Derisomaltose Patent Expiration
Ferric Derisomaltose is Used for treating iron deficiency anemia in adult patients with intolerance to oral iron or unsatisfactory response to oral iron, and non-hemodialysis dependent chronic kidney disease, by administering ferric derisomaltose. It was first introduced by Pharmacosmos As
Ferric Derisomaltose Patents
Given below is the list of patents protecting Ferric Derisomaltose, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Monoferric | US11633489 | Iron carbohydrate complex for treatment of iron deficiency of a fetus or an infant | Jun 22, 2036 | Pharmacosmos |
| Monoferric | US8815301 | Stable iron oligosaccharide compound | Aug 14, 2029 | Pharmacosmos |
| Monoferric | US10414831 | Stable iron oligosaccharide compound | Mar 25, 2029 | Pharmacosmos |
| Monoferric | US11851504 | Stable iron oligosaccharide compound | Mar 25, 2029 | Pharmacosmos |
| Monoferric | US12030962 | Stable iron oligosaccharide compound | Mar 25, 2029 | Pharmacosmos |
Ferric Derisomaltose's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Ferric Derisomaltose:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF) | Massachusetts General Hospital | NA |
COMPLETED
(Aug 1, 2026)
| PHASE2, PHASE3 |
| Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia | Pharmacosmos A/S | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Study of Ferric Derisomaltose Injection in Chinese Participants With Iron Deficiency Anemia Under Fasting Conditions | Sichuan Huiyu Pharmaceutical Co., Ltd | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1 |
| Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in HFpEF With Iron Deficiency | Government of Jersey | NA |
ENROLLING BY INVITATION
(Jun 1, 2026)
| PHASE2 |